Concepedia

Kumar Thakur

KT

Statistics

Publications

10

Citations

513

H-Index

10

Active since

2006

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (United Kingdom)

Advanced Pharma

Procter & Gamble (United States)

Kumar Thakur is an author at AstraZeneca (United States) specializing in drug discovery, medicinal chemistry, and pharmacology.

Publications per year

2006–2023

10

Publications

10

Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist

James S. Scott, Amber Balazs, Bernard Barlaam et al. · Journal of Medicinal Chemistry · 2020 · 111 citations · Full text

, , +17

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

Bernard Barlaam, Robert Casella, Justin Cidado et al. · Journal of Medicinal Chemistry · 2020 · 104 citations · Full text

, , +15

Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)

Michael P. Clark, Kelly M. George, Roger G. Bookland et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 55 citations · Full text

, , +11

Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo

James J. Dowling, Marat Alimzhanov, Larry Bao et al. · ACS Medicinal Chemistry Letters · 2013 · 53 citations · Full text

, , +17

Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization

James J. Dowling, Claudio Chuaqui, Timothy Pontz et al. · ACS Medicinal Chemistry Letters · 2012 · 47 citations · Full text

, , +17

1–5 of 10